Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Public And Private Partnerships Forge Way For China As Innovative Hub - DIA China Conference

This article was originally published in PharmAsia News

Executive Summary

BEIJING - With China's government poised to invest substantial funds in coming years to encourage innovative drug development, China is quickly becoming a favorite R&D destination for multinational pharmas, but both public and private players are still grappling with how to boost R&D productivity

You may also be interested in...

China To De-link Indigenous Innovation And Public Procurement Policies - U.S.-China Strategic And Economic Dialogue

WASHINGTON - In a positive move for the life sciences industry and others conducting business in China, Chinese leaders have agreed to de-link indigenous innovation policies from government procurement, a decision that - if fully implemented - would provide a fairer competitive environment for foreign-invested enterprises in China

Is China A Black Swan For Big Pharma? (Part 2 of 2)

[Editor's note: This is part two of a two part story; part one appeared in PharmAsia News, April 25, 2010.]

China's Center For Drug Evaluation Remakes Itself To Enter New Era Of Transparency, Speed Up Approvals

SHANGHAI - For years, China has talked about revising its drug review system to improve efficiency, and now major changes are in the works with China's State FDA reforming its drug review body, the Center for Drug Evaluation, to encourage drug innovation and facilitate globalization of its drug review process

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts